The global electronic data capture market size in 2026 is witnessing strong growth as clinical research continues to become increasingly digital, data-driven, and technology-enabled. According to Fortune Business Insights, the global electronic data capture market size was valued at USD 1.84 billion in 2025. The market is projected to grow from USD 2.07 billion in 2026 to USD 5.73 billion by 2034, exhibiting a CAGR of 13.57% during the forecast period. North America dominated the global electronic data capture market with a market share of 42.39% in 2025.
Electronic data capture (EDC) refers to a software-based system used to collect, manage, and store clinical trial data electronically instead of relying on paper-based forms. EDC platforms support clinical research organizations, pharmaceutical and biotechnology companies, hospitals, and research institutions by enabling structured data collection and management throughout clinical studies. The increasing volume of clinical trials and rising adoption of digital trial operations are supporting the expansion of the electronic data capture market.
Rising clinical trial volume and ongoing global research activity are among the primary factors supporting electronic data capture market growth. As clinical studies expand across multiple sites and countries, sponsors and contract research organizations require systems capable of capturing increasing numbers of patients, data points, and study records in a compliant and auditable manner. EDC platforms can also support faster deployment, standardized workflows, data cleaning, oversight, and ongoing study management.
Growing demand for EDC-related services is also contributing to market expansion. Study build, integrations, training, and support services are increasingly important as sponsors seek to maintain clinical trial timelines. In October 2024, Medidata announced Rave Lite to support growth across early- and late-stage clinical trials.
However, data privacy and cross-border restrictions can limit market expansion. Multinational clinical trials often require data to move between research sites, sponsors, CROs, and central data teams. Regulations governing patient-data storage, processing, and access can increase implementation complexity and require additional legal, information technology, validation, and documentation efforts.
At the same time, AI-assisted operations are creating new opportunities. AI can support repetitive activities such as data entry assistance, verification, document-to-structured-data extraction, and routine checks. In October 2025, Castor announced Castor Catalyst, an AI-powered platform designed to automate clinical study tasks and support human-supervised studies.
EHR-to-EDC interoperability is emerging as an important trend in the electronic data capture market. Direct movement of EHR data into EDC systems can reduce manual data entry and transcription, lower reconciliation requirements, and support improved data quality. Interoperability can also help enable hybrid and decentralized clinical trial execution by allowing data to be captured closer to routine care.
Cloud-based deployment is another significant development. Cloud/SaaS solutions offer scalability, remote access, integration with multiple data sources, and standardized vendor updates. In March 2024, Veeva announced that Veeva Vault EDC had surpassed 1,000 study starts, reflecting the growing adoption of cloud-based EDC platforms.
The global electronic data capture market is moderately consolidated, with leading vendors focusing on end-to-end clinical solutions, interoperability, compliance capabilities, and global deployment. Prominent companies include Veeva Systems Inc., Dassault Systèmes, Oracle, and IQVIA Inc. Other participants are focusing on differentiated modules, faster deployment, site usability, and partnerships that expand their technology ecosystems.
Veeva Systems Inc.; Dassault Systèmes; Oracle; IQVIA Inc.; Medrio; OpenClinica, LLC; Castor; Viedoc Technologies; ClinCapture; CRSCUBE INC.
By Component (Software and Services)
By Deployment (Cloud/SaaS and On-premise)
By Development Phase (Phase I, Phase II, Phase III, and Phase IV)
By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Hospitals & Clinics, Academic & Research Institutes, and Others)